Sanofi’s Sutimlimab Shows Promise In Rare Blood Disorder
First-In-Class Complement Pathway Inhibitor Impresses In Cold Agglutinin Disease
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
